Arcellx, Inc. (ACLX)
NASDAQ: ACLX · Real-Time Price · USD
71.98
+1.14 (1.61%)
At close: Dec 10, 2025, 4:00 PM EST
72.05
+0.07 (0.10%)
After-hours: Dec 10, 2025, 7:42 PM EST
Arcellx Revenue
Arcellx had revenue of $4.95M in the quarter ending September 30, 2025, a decrease of -80.99%. This brings the company's revenue in the last twelve months to $35.90M, down -76.96% year-over-year. In the year 2024, Arcellx had annual revenue of $107.94M, down -2.16%.
Revenue (ttm)
$35.90M
Revenue Growth
-76.96%
P/S Ratio
111.03
Revenue / Employee
$220,233
Employees
163
Market Cap
4.16B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 107.94M | -2.38M | -2.16% |
| Dec 31, 2023 | 110.32M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ACLX News
- 1 day ago - Cancer Study Buoys These Small Biotechs - Barrons
- 2 days ago - Why Is Arcellx Stock Surging Today? - Benzinga
- 3 days ago - Arcellx, Inc. (ACLX) Discusses Phase 2 iMMagine-1 Study Results and Multiple Myeloma Treatment Advances Transcript - Seeking Alpha
- 4 days ago - Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma - Business Wire
- 22 days ago - Arcellx to Host Investor Relations Event During the 67th ASH Annual Meeting and Exposition - Business Wire
- 5 weeks ago - Arcellx Provides Third Quarter 2025 Financial Results - Business Wire
- 5 weeks ago - Arcellx to Present New Data for Its iMMagine-1 Study and Continues Scientific Momentum with Multiple Presentations at the 67th ASH Annual Meeting and Exposition - Business Wire
- 3 months ago - Arcellx, Inc. (ACLX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha